pulmonary vasoreactivity

Calcium channel antagonists have limited utility in the treatment of PAH and are reserved for patients who demonstrate vasoreactivity in response to a short-acting pulmonary vasodilator, defined as a reduction in the mean pulmonary artery pressure by ≥10 mm Hg and reaching an absolute mean pulmonary arterial pressure of ≤40 mm Hg. Because this patient does not exhibit pulmonary vasoreactivity, treatment with the calcium channel antagonist nifedipine would not be of utility (choice D is incorrect).1

Footnotes

  1. SEEK Questionnaires ↩